𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Optimal use of the 131-I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma

✍ Scribed by Renato Mastrangelo; Assunta Tornesello; Anna Lasorella; Antonio Iavarone; Stefano Mastrangelo; Riccardo Riccardi; Luca Diociaiuti; Vittoria Rufini; Andrea Pession; Luigi Troncone

Book ID
110229075
Publisher
Springer US
Year
1997
Tongue
English
Weight
38 KB
Volume
31
Category
Article
ISSN
0167-594X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

I-131 metaiodobenzylguanidine: Diagnosti
I-131 metaiodobenzylguanidine: Diagnostic use in neuroblastoma patients in relapse
✍ Heyman, Sydney ;Evans, Audrey E. ;D'Angio, Giulio J. πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 420 KB

Metaiodobenzylguanidine (MIBG) has been used for the detection and treatment of neuroectodermal tumors, including neuroblastoma. We report our experience with I3'l- MIBG used diagnostically in neuroblastoma patients with relapse. Thirtyeight studies were performed in 26 patients. There were 24 child

Position paper: Role of131I-metaiodobenz
Position paper: Role of131I-metaiodobenzylguanidine in the treatment of neuroblastoma
✍ Mastrangelo, Renato; Tornesello, Assunta; Mastrangelo, Stefano πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 67 KB πŸ‘ 1 views

Background. Standard chemo-radiotherapy methods for the treatment of children with advanced neuroblastoma (NBL) including bone marrow transplant approaches have been disappointing. These poor results can be ascribed to the evolution of residual drug-resistant cell populations. Curative attempts shou

Therapeutic use of131I-metaiodobenzylgua
Therapeutic use of131I-metaiodobenzylguanidine (MIBG) in neuroblastoma: A phase II study in nine patients
✍ Hartmann, O. ;Lumbroso, J. ;Lemerle, J. ;Schlumberger, M. ;Ricard, M. ;Aubert, B πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 576 KB

Effects of high activities of I 131 meta-iodobenzylguanidine (mIBG) were evaluated in nine children with advanced neuroblastoma. All patients had been previously heavily treated and had either primarily refractory disease or resistant relapse. Twenty-two doses of mIBG labeled with 1.3 to 4 GBq (35-1